1、vnovotech-MARCH 7,2024Acute Myeloid Leukaemia-Global Clinical Trial Landscape(2024)North America and Europe conducted over 60%of AML trials,led by the US and Spain,respectivelyAsia-Pacific contributed over 30%of AML trials,led by Mainland China and AustraliaThe Asia-Pacific region shows shorter recr

2、uit-ment durations and faster recruitment rates compared to Europe and the USAML is a malignant condition afecting blood-forming stem cells,causing abnormal myeloid growth Primarily afect adults,comprising over 30%of leukemia casesApproved drugs like Midostaurin,Gilteritinib,and Venetoclax target sp

3、ecific mutations in AML,providing efective options for relapsed casesPromising investigational immunotherapies,such as BiTE antibodies and CAR-T Cell Therapy targeting CD33 and CD123,prioritize tailored AML treatmentsIn Asia,Mainland China reported a relatively high incidence,indicating a substantia

4、l burdenThe US ranks among the top countries for AML incidence,alongside Mainland ChinaIn Europe,Germany and France reported a relatively higher incidence of AMLThe content of this publication is proprietary to Novotech Health Holdings.No part of this publication may be reproduced,distributed,or tra

5、nsmitted in any form or by any means,including photocopying,recording,or other electronic or mechanical methods,without the prior written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses.Please note that this copyright statement applies specifically

6、 to this publication and its content and does not extend to other materials or intellectual property owned by Novotech.Any unauthorized reproduction or distribution of this publication or any portion thereof may result in legal action taken by Novotech to protect its rights.For permissions or inquir